TrialPath
Recruiting

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505 · Gilead Sciences
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Multicenter, First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)
About this study
The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives of this study are: Phase 1: To determine the safety and tolerability of TUB-040 and determine the maximum tolerated dose (MTD) or the identified dose for optimization (IDO). Phase 2a: To assess safety of TUB-040, the preliminary efficacy of TUB-040, and to identify the recommended phase II dose (RP2D) for further development of TUB-040 . Phase 2b: To determine the efficacy of TUB-040 in patients with PROC.
Eligibility criteria
Key Inclusion Criteria (for all phases) 1. Male or non-pregnant, non-breastfeeding female, age 18 years or older at the date of consent. 2. Disease not amenable to curative intent treatment. 3. Individuals have exhausted the standard of care treatment (SoC) with expected survival benefit and are not denied SoC with expected survival benefit by participating in the trial. 4. Individuals with previous systemic topoisomerase I inhibitor treatment (e.g., Topotecan) are allowed in the study. 5. Radiologically measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the INV. 6. Eastern Cooperative Oncology Group (ECOG) 0-1. 7. Have a life expectancy of more than 12 weeks for disease-related mortality, as evaluated by the INV. 8. Individuals must be willing to sign an archival tissue release form for research purposes and determination of biomarker expression. 9. Individuals must be willing to undergo a non-contrast high resolution computed tomography (HRCT) of the thorax scan and pulmonary function testing (PFT) at screening. 10. Adequate organ function 11. Resolution of all acute toxic effects of prior therapy or surgical procedures to ≤grade 1 (except alopecia, hyperpigmentation, or discoloration (incl. vitiligo) of the skin and nails, stable immune-related toxicity such as hypothyroidism on hormone replacement, adrenal insufficiency on ≤10 mg daily prednisone \[or equivalent\], chronic grade 2 peripheral sensory neuropathy after prior taxane therapy or anticancer treatment such as but not limited to immune oncology therapy (IOs)). 12. Individuals of childbearing potential (FCBP) who are sexually active with a non-sterilized partner must use at least one highly effective method of contraception from the time of screening and must agree to continue using such precautions until the end of exposure, plus 5 half-lives and 6 months add-on in the case of individuals assigned female at birth. 13. In the opinion of the investigator, the individual must be able to understand, give written informed consent, and comply with all study-related procedures, medication use, and evaluations. 14. The individual must not have a history of non-compliance with medical regimens or be considered potentially unreliable and/or uncooperative. 15. The individual must be willing to sign and date the informed consent form (ICF) Key Exclusion Criteria (for all phases) 1. The individual is pregnant, lactating or breastfeeding or has a positive serum pregnancy test during the screening period. 2. History of hypersensitivity to exatecan or excipients of the TUB-040 formulation. 3. Individuals are not allowed to participate in interventional clinical studies either concurrently or within the previous 28 days or within 5 half-lives of any investigational pharmacologic agents or imaging materials, including dyes, investigational surgical techniques, or devices. 4. Individuals with spinal cord compression or active central nervous system disease, and/or carcinomatous meningitis. 5. Prior radiotherapy \<2 weeks from trial inclusion. 6. Major surgery within 21 days prior to signing the ICF, unless the individual is recovered at that time. 7. Has a history of non-infectious interstitial lung disease/pneumonitis (ILD)/pneumonitis/radiation pneumonitis that required steroids or has current ILD/pneumonitis. 8. Has an oxygen saturation of \<93% on room air at rest. 9. Has a QTcF \>470 ms 10. History of nephrotic syndrome 11. Active corneal disease, or history of corneal disease within 12 months prior to enrollment. 12. Active, uncontrolled or severe impairment of the urogenital, renal, hepatobiliary, cardiovascular, gastrointestinal, neurologic, or hematopoietic systems which, in the opinion of the investigator, would predispose the individual to the development of complications from the administration of protocol therapy. 13. History of another malignancy with ongoing treatment or not yet free from disease for 2 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or other malignancy with a similar expected curative outcome. 14. Documented other concurrent non-malignant comorbidities such as unstable or uncontrolled pectoral angina, myocardial infarction during the last 6 months, valvular heart disease that requires treatment, acute myocarditis, or congestive heart failure (CHF) (New York Heart Association III or IV). 15. Any anti-tumor chemotherapy, systemic anti-cancer therapy, radiotherapy (except for local radiation therapy of lesions that may cause imminent complications), hormonal therapy, immunotherapy, or corticoid therapy. 16. Concurrent use of strong inhibitors or strong inducers of CYP3A4 17. Live vaccines within 30 days prior to study entry. 18. Individuals with acute or chronic infections such as: 1. Individuals who are HBsAg positive are eligible if they have received Hepatitis B virus (HBV) anti-viral therapy for at least 4 weeks and have an undetectable HBV viral load prior to randomization. 2. Individuals with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening. 3. HIV infected individuals must be on anti-retroviral therapy (ART) and have a well-controlled HIV infection/disease 4. Any other known unresolved and active bacterial, viral, fungal, mycobacterial, or other infection at screening. 5. History of severe and recurrent infections per INV judgment. 6. History of progressive multifocal leukoencephalopathy Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study design
Enrollment target: 334 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2024-06-12
Estimated completion: 2027-12
Last updated: 2026-11-03
Interventions
Drug: TUB-040Drug: Bevacizumab
Primary outcomes
  • • Phase 1: Percentage of Participants Experiencing any Dose-limiting Toxicities (DLTs) (First dose up to 21 days)
  • • Phase 1 and 2a: Percentage of Participants Experiencing Treatment-Emergent Adverse Event (TEAEs) (First dose date up to 30 days post last dose (Up to 3 years))
  • • Phase 2a & 2b: Overall Response Rate (ORR) by Blinded Independent Central Review (BICR) (Up to 3 years)
Sponsor
Gilead Sciences · industry
Contacts & investigators
ContactGilead Clinical Study Information Center · contact · GileadClinicalTrials@gilead.com · 1-833-445-3230 (GILEAD-0)
InvestigatorGilead Study Director · study_director, Gilead Sciences
All locations (21)
University of Alabama at BirminghamRecruiting
Birmingham, Alabama, United States
Winship Cancer Institute Emory UniversityRecruiting
Atlanta, Georgia, United States
Dana Farber Cancer Institute (DFCI)Recruiting
Boston, Massachusetts, United States
START New Jersey (Astera Cancer Center)Recruiting
East Brunswick, New Jersey, United States
Mount SinaiRecruiting
New York, New York, United States
The Christ Hospital Physicians - Mt. AuburnRecruiting
Cincinnati, Ohio, United States
Ohio State University CRSRecruiting
Columbus, Ohio, United States
Stephenson Cancer CenterRecruiting
Oklahoma City, Oklahoma, United States
Asante Rogue Region al Medical CenterRecruiting
Medford, Oregon, United States
START Dallas Fort WorthRecruiting
Fort Worth, Texas, United States
NEXT Oncology DallasRecruiting
Irving, Texas, United States
START Mountain RegionRecruiting
West Valley City, Utah, United States
NEXT VirginiaRecruiting
Fairfax, Virginia, United States
UZ Leuven - PPDSRecruiting
Leuven, Belgium
Charité- Universitaetsmedizin BerlinRecruiting
Berlin, Germany
University Hospital of CologneRecruiting
Cologne, Germany
ARENSIA Exploratory Medicine, LLCRecruiting
Cluj-Napoca, Romania
Clínica Universidad de Navarra - MadridRecruiting
Madrid, Spain
NEXT Madrid, University Hospital Quironsalud MadridRecruiting
Madrid, Spain
ARENSIA Exploratory Medicine, LLCActive Not Recruiting
Kyiv, Ukraine
Guy's HospitalActive Not Recruiting
London, United Kingdom
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC · TrialPath